NASDAQ (usa) |
![]() |
6715.56 | -12.11 | -0.18% |
FTSE 100 (london) |
![]() |
7487.96 | -5.12 | -0.07% |
DAX (german) |
![]() |
13465.51 | 235.94 | 1.78% |
NIKKEI 225 (japan) |
![]() |
22420.08 | 408.47 | 1.86% |
Hang - Seng (hong kong) |
![]() |
28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) |
![]() |
3391.61 | 17.53 | 0.52% |
KOSPI (korea) |
![]() |
2556.47 | 33.04 | 1.31% |
All Ordinaries (australia) |
![]() |
6005.30 | 28.90 | 0.48% |
BOVESPA (brazil) |
![]() |
74092.76 | -215.73 | -0.29% |
Provexis plc (LSE: PXS)
PXS Technical Analysis
3
As on 14th May 2025 PXS STOCK Price closed @ 0.56 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.62 & Sell for SHORT-TERM with Stoploss of 0.66 we also expect STOCK to react on Following IMPORTANT LEVELS. |
PXSSTOCK Price
Open | 0.52 | Change | Price | % |
High | 0.56 | 1 Day | 0.04 | 7.69 |
Low | 0.52 | 1 Week | -0.01 | -1.75 |
Close | 0.56 | 1 Month | 0.11 | 24.44 |
Volume | 68008 | 1 Year | 0.06 | 12.00 |
52 Week High 0.81 | 52 Week Low 0.45 |
LSE UK Most Active Stocks
EME | 0.04 | -55.56% |
MSMN | 0.06 | -14.29% |
PREM | 0.03 | 0.00% |
UKOG | 0.01 | 0.00% |
VRS | 0.03 | -25.00% |
ENET | 0.02 | 0.00% |
MIRI | 0.02 | 0.00% |
CPX | 0.14 | -6.67% |
ORCP | 0.02 | 0.00% |
DEMG | 0.02 | -50.00% |
LSE UK Top Gainers Stocks
LSE UK Top Losers Stocks
PXS Daily Charts |
PXS Intraday Charts |
Whats New @ Bazaartrend |
PXS Free Analysis |
|
PXS Important Levels Intraday
RESISTANCE | 0.64 |
RESISTANCE | 0.61 |
RESISTANCE | 0.60 |
RESISTANCE | 0.58 |
SUPPORT | 0.54 |
SUPPORT | 0.52 |
SUPPORT | 0.51 |
SUPPORT | 0.48 |
PXS Forecast May 2025
4th UP Forecast | 1.23 |
3rd UP Forecast | 1.02 |
2nd UP Forecast | 0.88 |
1st UP Forecast | 0.75 |
1st DOWN Forecast | 0.37 |
2nd DOWN Forecast | 0.24 |
3rd DOWN Forecast | 0.1 |
4th DOWN Forecast | -0.11 |
PXS Weekly Forecast
4th UP Forecast | 1.31 |
3rd UP Forecast | 1.07 |
2nd UP Forecast | 0.92 |
1st UP Forecast | 0.77 |
1st DOWN Forecast | 0.35 |
2nd DOWN Forecast | 0.20 |
3rd DOWN Forecast | 0.05 |
4th DOWN Forecast | -0.19 |
PXS Forecast2025
4th UP Forecast | 1.5 |
3rd UP Forecast | 1.2 |
2nd UP Forecast | 1.01 |
1st UP Forecast | 0.83 |
1st DOWN Forecast | 0.29 |
2nd DOWN Forecast | 0.11 |
3rd DOWN Forecast | -0.08 |
4th DOWN Forecast | -0.38 |
Provexis plc ( LSE UK Symbol : PXS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
PXS Other Details
Segment | EQ | |
Market Capital | 18128724.00 | |
Sector | Healthcare | |
Industry | Drug Manufacturers-Specialty & Generic | |
Offical website | > echo $website ; ?> |
PXS Address
![]() |
PXS Latest News
PXS Business Profile
Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom. Address: 2 Blagrave Street, Reading, United Kingdom, RG1 1AZ
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service